Steris’s niche is a lucrative one

Article Excerpt

The COVID-19 pandemic resulted in short-term disruptions to elective medical procedures. But despite that, hospital-equipment supplier Steris has gone on to hit new highs. Now, the company is in a great position to profit from favourable long-term demographic trends such as an aging population. And with two recent key acquisitions, it has expanded into lucrative new markets. We think this Power Buy is poised to keep moving even higher for our subscribers. STERIS PLC, $214.96, is a buy. The firm (New York symbol STE; TSINetwork Rating: Extra Risk) (www.steris.com; Shares outstanding: 99.8 million; Market cap: $21.5 billion; Dividend yield: 0.8%) sells sterilization equipment, surgical tables, and other products and services used in hospitals and laboratories. The company operates in four segments: Healthcare Products (47% of revenues), Applied Sterilization Technologies (21%), Healthcare Specialty Services (19%), and Life Sciences (13%). Although based in the U.K., it generates 73% of its revenue from the U.S. market. On June 2, 2021, Steris completed the acquisition of New…